Angstrom Pharmaceuticals is Drug Discovery in United States that focus on hematological malignancies business. Founded in 1996. They cover business area such as developer, pharmaceutical drug, metastatic disease, hematological malignancy, clinical development, treatment, ovarian cancer, chronic lymphocytic leukemia, patient, diabetic retinopathy, age-relate macular degeneration.
1996
( 28 years old in 2024 )
Hematological Malignancies
-
990 Highland Drive
Suite 110V
Solana Beach, CA 92075
United States
Private
developerpharmaceutical drugmetastatic diseasehematological malignancyclinical developmenttreatmentovarian cancerchronic lymphocytic leukemiapatientdiabetic retinopathyage-relate macular degeneration
* We use standard office opening hours in near Angstrom Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Angstrom Pharmaceuticals is Drug Discovery business from United States that founded in 1996 (28 years old in 2024), Angstrom Pharmaceuticals business is focusing on Hematological Malignancies.
Angstrom Pharmaceuticals headquarter office and corporate office address is located in 990 Highland Drive Suite 110V Solana Beach, CA 92075 United States.
Angstrom Pharmaceuticals was founded in United States.
In 2024, Angstrom Pharmaceuticals is currently focus on hematological malignancies sector.
Above is snippet of Google Trends for "hematological malignancies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Angstrom Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
